Premium Nahrungsergänzungsmittel | artgerecht

Bundibugyo Ebolavirus: Symptoms, Causes & Treatment

Bundibugyo ebolavirus (BDBV) is a rare and highly dangerous species of the genus Ebolavirus that causes severe hemorrhagic fever in humans.

Regular tips about health Regular tips about health

Things worth knowing about "Bundibugyo ebolavirus"

Bundibugyo ebolavirus (BDBV) is a rare and highly dangerous species of the genus Ebolavirus that causes severe hemorrhagic fever in humans.

What is Bundibugyo Ebolavirus?

Bundibugyo ebolavirus (abbreviated BDBV) is one of several distinct species within the genus Ebolavirus, belonging to the family Filoviridae. It was first identified in 2007 during an outbreak in the Bundibugyo District of western Uganda. BDBV causes Ebola virus disease (EVD), a life-threatening illness characterized by severe hemorrhagic fever and high mortality rates.

Discovery and Classification

In the autumn of 2007, an outbreak of a severe hemorrhagic illness emerged in the Bundibugyo region of Uganda. Genomic sequencing confirmed that the causative agent was a previously unknown ebolavirus species. Bundibugyo ebolavirus was subsequently classified as the fifth species of the genus Ebolavirus. It shares genetic similarities with Tai Forest ebolavirus but is genetically distinct from other species such as Zaire ebolavirus and Sudan ebolavirus.

Causes and Transmission

Like other ebolaviruses, BDBV is primarily transmitted through direct contact with the bodily fluids of infected individuals or animals. Key transmission routes include:

Direct contact with blood, saliva, urine, feces, or other bodily fluids of infected persons
Contact with infected animals, particularly bats and non-human primates (zoonotic transmission)
Unsafe burial practices involving direct contact with the deceased
Nosocomial (healthcare-associated) transmission in settings with inadequate infection control

The exact natural reservoir of Bundibugyo ebolavirus has not been definitively identified, but fruit bats of the family Pteropodidae are considered the most likely reservoir hosts, as is the case with other ebolavirus species.

Symptoms

The incubation period ranges from 2 to 21 days. Clinical manifestations of BDBV infection typically include:

Sudden onset of high fever
Severe headache and muscle pain
Nausea, vomiting, and diarrhea
Skin rash
Impaired kidney and liver function
In severe cases: internal and external bleeding (hemorrhagic manifestations)

Compared to Zaire ebolavirus, BDBV is considered somewhat less lethal, though the case fatality rate was approximately 25–36% during the 2007 outbreak, which remains extremely high.

Diagnosis

Clinical symptoms are initially non-specific and may overlap with other tropical infectious diseases. Laboratory-based diagnostic methods are therefore essential:

RT-PCR (reverse transcriptase polymerase chain reaction): detects viral RNA in blood samples
ELISA: detects viral antigens or antibodies against the virus
Virus isolation under BSL-4 conditions (the highest biosafety level)

All diagnostic samples must be handled and transported under strict biosafety protocols.

Treatment

There is currently no specifically approved treatment for Bundibugyo ebolavirus infection. Management is primarily supportive and symptomatic:

Intravenous fluid replacement and electrolyte management
Treatment of secondary infections
Intensive care support in severe cases

Therapeutic agents and monoclonal antibodies developed against Zaire ebolavirus (such as atoltivimab/maftivimab/odesivimab) may not provide full cross-protection against BDBV, highlighting the need for broadly effective treatment approaches. Similarly, approved vaccines such as rVSV-ZEBOV are primarily targeted against Zaire ebolavirus and may not offer adequate protection against BDBV.

Epidemiology and Known Outbreaks

Bundibugyo ebolavirus has been responsible for two documented outbreaks to date:

Uganda 2007–2008: The first outbreak occurred in Bundibugyo District, with 149 confirmed and probable cases and 37 deaths.
Democratic Republic of the Congo 2012: An outbreak in Orientale Province resulted in 57 cases and 29 deaths.

While BDBV outbreaks have been smaller in scale than those caused by Zaire ebolavirus, they represent a serious public health threat due to the high case fatality rate and the absence of a targeted therapy.

Prevention

As no specifically effective vaccine against BDBV is currently available, prevention relies on:

Strict adherence to infection prevention and control measures (personal protective equipment, PPE)
Isolation of confirmed or suspected cases
Safe burial practices
Community education and awareness in at-risk regions
Robust surveillance systems and rapid outbreak response by public health authorities

References

Towner JS et al. - Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathogens. 2008;4(11):e1000212.
World Health Organization (WHO) - Ebola virus disease. Fact Sheet. WHO, Geneva, 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
Centers for Disease Control and Prevention (CDC) - Known Cases and Outbreaks of Ebola Virus Disease. CDC, Atlanta, 2023. Available at: https://www.cdc.gov/vhf/ebola/history/chronology.html

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.